Impact BioMedical (IBO) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
NextCure (NXTC) has outperformed Impact BioMedical (IBO) over the past year, gaining 10.0% versus a loss of 46.3%. Impact BioMedical is the larger company by market cap ($36.3 million vs $32.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IBO | NXTC |
|---|---|---|
| Share price | $4.25 | $7.18 |
| Market cap | $36.31M | $32.87M |
| 1-day change | +3.41% | +5.90% |
| YTD return | -33.51% | -49.40% |
| 1-year return | -46.28% | +9.95% |
| 5-year return | — | -93.15% |
| P/E ratio (TTM) | 0.37 | — |
| EPS (TTM) | $11.48 | $-8.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.51 | $15.74 |
| 52-week low | $4.06 | $1.55 |
| Distance from 52-week high | -59.55% | -54.38% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +178.55% |
| Average volume | 11.88K | 2.11M |
| Shares outstanding | 8.54M | 4.58M |
| Employees | 2 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed IBO by 56.2 percentage points over the past year.
About Impact BioMedical
IBO stock →Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
IBO vs NXTC FAQ
Which is bigger, Impact BioMedical or NextCure?
Impact BioMedical (IBO) is larger, with a market capitalization of $36.31M compared with $32.87M for NextCure (NXTC).
Which stock has performed better over the past year, IBO or NXTC?
NXTC returned +9.95% over the past 12 months, compared with -46.28% for IBO (price return, excluding dividends). Past performance does not predict future results.
Are Impact BioMedical and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.